ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Lingor P, Koch J, Ludolph A, Frontini R, Blankenstein C, Bidner H, Kuzma-Kozakiewicz M, Benatar M, Günther R, Neuwirth C, Leha A, Hilgers R, Friede T, Camu W, Weber M, ROCK-ALS Investigators. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol 2019; 10:293.
27.03.2019
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
27.03.2019
Front Neurol 2019; 10:293
Lingor Paul, Koch Jan C, Ludolph Albert, Frontini Roberto, Blankenstein Christiane, Bidner Helen, Kuzma-Kozakiewicz Magdalena, Benatar Michael, Günther René, Neuwirth Christoph, Leha Andreas, Hilgers Reinhard, Friede Tim, Camu William, Weber Markus, ROCK-ALS Investigators
Weiter
